A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations
for
Multiple Myeloma
Location: New York NY, Chapel Hill NC, Winston-Salem NC,
Sponsor: AbbVie
Sex: All
Age: 18+
Code: NCT06892522
Phase1, Phase2, Recruiting
Featured
Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma
for
Multiple Myeloma
Location: New York NY, New Brunswick NJ, Montreal,
Sponsor: AbbVie
Sex: All
Age: 18+
Code: NCT06896916
Phase1, Recruiting
Featured
A Study to Evaluate Adverse Events, Change in Disease Activity, Tolerability, and How Intravenous ABBV-438 Moves Through the Body in Adult Participants With Multiple Myeloma (MM)
for
Multiple Myeloma
Location: Tampa FL, Newnan GA, Grand Rapids MI, Denver CO,
Sponsor: AbbVie
Sex: All
Age: 18+
Code: NCT07409246
Phase1, Recruiting
Beta Glucan's Effect on Pembrolizumab Immunologic Response in Stage III-IV Melanoma
for
Melanoma Stage III, Melanoma Stage IV
Location: Louisville KY
Sponsor: Kelly McMasters
Sex: All
Age: 18+
Code: NCT04513028
Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
Featured
A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
for
Multiple Myeloma
Location: New York NY, Fairfax VA, Chapel Hill NC, Roanoke VA,
Sponsor: AbbVie
Sex: All
Age: 18+
Code: NCT07095452
Phase2, Phase3, Recruiting
Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)
Long-term Brain Stimulation of the Motor Ventral Thalamus (VOP/VIM) to Improve Motor Function
for
Traumatic Brain Injury, Stroke, Brain Disease,
Location: Pittsburgh PA
Sponsor: Jorge Gonzalez-Martinez
Sex: All
Age: 18 - 70+
Code: NCT07056348
Recruiting
Q702 for the Treatment of Patients With Hematologic Malignancies
for
Hematopoietic and Lymphatic System Neoplasm,
Location: Rochester MN, Scottsdale AZ
Sponsor: Mayo Clinic
Sex: All
Age: 18+
Code: NCT06712810
Phase1, Recruiting
CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
for
Diffuse Midline Glioma, H3 K27-Altered,
Location: Boston MA, Valhalla NY, New York NY, Philadelphia PA,
Sponsor: Children's Oncology Group
Sex: All
Age: 1 - 21
Code: NCT04870944
Phase1, Phase2, Recruiting
Exploring the Feasibility of Cerebrospinal Fluid (CSF) and Blood Plasma Liquid Biopsy in Patients With Metastatic Solid Tumours and Primary Central Nervous System (CNS) Tumours: A Pilot Study
for
Solid Tumor Malignancies, Brain Metastasases,
Location: Toronto
Sponsor: Sunnybrook Health Sciences Centre
Sex: All
Age: 18+
Code: NCT07476781
Recruiting
Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma
for
Recurrent Glioblastoma,
Location: Bethesda MD
Sponsor: National Institute of Neurological Disorders and Stroke (NINDS)
Sex: All
Age: 18 - 70+
Code: NCT07416188
Phase1, Phase2, Recruiting
Illuminate: A Clinical Study Evaluating CAR T Immune Cell Therapy (BCB-276) for Patients With Diffuse Intrinsic Pontine Glioma (DIPG).